Phesi has announced that its artificial intelligence (AI)-driven Trial Accelerator platform has reached a critical milestone of now containing global data from more than 100 million patients.
The volume will allow sponsors to access data on patients with over 4,000 indications, plan more successful trials and simulate clinical development activity more accurately.
Phesi’s Trial Accelerator works to deliver digitalised patient data to enhance or replace those collected from clinical trials.
Across the past two decades, data has been collated from product and disease registries, electronic health records, medical claims data and data gathered from around 100,000 dynamically updated sources.
The platform powers the Phesi Patient Access Score, Diversity, Equity and Inclusion Data Service and the Digital Patient Profile.
“We have been gathering and structuring a wealth of data for sponsors and clinical trial planners,” said Dr Gen Li, president at Phesi.
He added: “Phesi is able to identify where and when specific data was generated, by whom and how to provide contextualised data that delivers precision, insights and certainty to clinical development teams.”
In addition, Phesi has published the second edition of its Digital Patient Profile (DPP) catalogue, which helps deliver a statistical view of patient attributes to improve protocol design and accelerate the adoption of digital trial arms.
The DPP now includes relapsed or refractory follicular lymphoma, CDKL5, chronic migraine, episodic migraine, stroke, acute ischaemic and acute coronary syndrome, as well as 22 other prevalent diseases and 12 oncology profiles.
The second edition also contains granular patient data across 34 indications, both at cohort level and patient level, and will be used by sponsors to develop Digital Twins and Digital Trial Arms as part of clinical development strategies.
Jonathan Peachey, chief operating officer and board director at Phesi, said: “We are continually refining the methodology by which we create patient profiles” and to “empower sponsors to make data-led decisions in the trial planning process”.
